Topotarget UK Limited

Topotarget A/s

Antianthra Aps

Topo Target Aps

Biocodex

Maxwell Sehested

Peter Buhl Jensen

Henri Lichenstein

James Ritchie

Kamille Dumong Erichsen

Xiaozhang Qian

Mike Jeffers

Paul Kristjansen

Annemette Thougaard

Seppo W Langer

Kenneth Hofland

Nis Nissen

Kamille Dumong Petersen

Lars Hollund Jensen

The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need thereof a first amount or dose of a histone deacetylase (HDAC) inhibitor, such as PXD-101, and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (EGFR) inhibitor, such as Tarceva&#xda;, wherein the first and second amounts or doses together comprise a therapeutically effective amount.

Combination therapies using HDAC inhibitors

The present invention relates to a method of treatment of a tumour cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane wherein said subject is further treated with radiation.

Cancer treatment with topoisomerase-II inhibitor, a bis-dioxypiperazine and radiation

The present invention relates to a method for pharmacological treatment of accidental extravasation of topoisomerase II poisons, such as anthracyclines. In particular, the invention relates to the use of a topo II catalytic inhibitor, such as the bisdioxopiperazine ICRF-187, for the treatment of an accidental extravasation of a topoisomerase II poison. A method for treatment of such extravasation of a topoisomerase poison such as the anthracyclines, daunorubicin, doxorubicin, epirubicin, or idarubicin is disclosed.

Treatment of accidental extravasation of anthracyclines

The present invention relates to a method for selectively killing tumor or metastatic cells within a defined compartment of the organism of a large mammal, in particular a human, said method comprising administering to a mammal an effective tumor&mdash;or metastasis-killing amount of a topoisomerase II poison except doxorubicin, and protecting non-tumorous tissue of the mammal against the toxic action of the topoisomerase II poison by administration of a bis-dioxypiperazine compound. In particular, the invention relates to a pharmaceutical kit for selectively killing tumor or metastatic cells within the central nervous system in a large mammal, in particular a human, said kit comprising: a) a dosage unit of a bis-dioxypiperazine and a pharmaceutically acceptable carrier, and b) a dosage unit of topoisomerase II poisons except doxorubicin and a pharmaceutically acceptable carrier.

Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy

Growing community of inventors

Copenhagen, Denmark

Maxwell Sehested